Get started

Cara Therapeutics, Inc.

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

CARA chart

Key stats

Market capitalization
55.57MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.16USD
Net income
−85.474MUSD
Revenue
41.867MUSD
Shares float
46.225M
Beta
2.62

About Cara Therapeutics, Inc.

Sector
Health Technology
Industry
Biotechnology
CEO
Christopher A. Posner
Website
caratherapeutics.com
Headquarters
Stamford
Employees (FY)
106
Founded
2004
ISIN
US1407551092
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Ideas

Cara Therapeutics Announces Positive Topline ResultsCARA: Cara Therapeutics, Inc. 2022-06-30 07:00:00 Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Nostalgia Paresthetica
Long
by MarketMoversReport
1
CARA Cloud Pop Already Re-test Cloud Ready!On the 4hr and 8 hr there are low signals puddling up all over the place. This is ready to pop. In the Past the lowest pop witht hese same signals was 61% move. Taking this to at the lowest $16.85 by iCantw84it 03.26/22
Long
by iCantw84it
2
$CARA - suport level$CARA - The stock has had a support level of $11.9 since '17. It only went lower in March '20. Now it has also fallen a bit lower, but it is trying to get back up. If you buy at the current level, stop below $10.8, with $15.5 and $17.8 as growth targets. Its not an investment recommendation
by kovpups
Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection ACARA: Cara Therapeutics, Inc. 2022-01-10 08:00:00 Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
Long
by RocketTickers
CARA and Weed heating upthis could go anyway at the moment but strong volume and huge gap to fill on this chart but we have earnings coming out Monday after hours so could pump if beats or could act as a good price entry for long swing. Im holding calls for the move over 18.15 I want 20+.
Long
by bouncy49
$CARA Target 17.68 for 24.42%$CARA Target 17.68 for 24.42% Or double position at 10.74 I'm not sure if I published this one when I first bought on that hellacious dip, haha. 🤣 Anyway, it looks like it found a little bit of support here so, might as well publish it here This might not be a trade you want to play... I will pos
Long
by LadyAmalthea12

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
Earnings
Next:—
‪0‬

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.4Very Good
Learn more

See all brokers